Every Form 4 that Avanos Medical, Inc. (AVNS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVNS filings page.
Sigfrido Delgado, SVP, Operations of Avanos Medical, reported merger-related dispositions of his equity awards. On July 27, 2026, 55,741 common shares, including 40,335 time-based RSUs, were converted into the right to receive $25.00 in cash per share under an Agreement and Plan of Merger.
Performance-based RSUs for 54,886 shares were similarly converted at the Merger Consideration, with a maximum of 72,282 shares possible if 2026 performance exceeds target. Stock options covering 37,520 shares at $13.69 and 21,914 shares at $15.24 were canceled and converted into cash based on $25.00 minus the exercise price per share. The Rule 10b5-1 checkbox was not marked.
Avanos Medical SVP and Chief Financial Officer Scott Michael Galovan reported merger-related equity conversions tied to a transaction that converted each share of common stock into the right to receive $25.00 per share in cash. A total of 135,596 shares of common stock, including time-based restricted stock units, were exchanged for this cash consideration.
Performance-based restricted stock units representing 96,121 shares were deemed acquired and disposed at target performance, with a maximum potential of 127,534 shares if 2026 performance exceeds target. Employee stock options on 69,630 and 21,038 shares, with exercise prices of $13.6900 and $15.2400 respectively, were canceled and converted into cash equal to their in-the-money value, while options with exercise prices above $25.00 were canceled for no consideration.
Avanos Medical CEO David Pacitti reported transactions tied to a merger effective July 27, 2026. Each common share was converted into the right to receive $25.00 per share in cash. He disposed of 322,194 common shares (including time-based RSUs) and 444,730 performance-based RSUs in deemed acquire-and-dispose entries, all for $25.00 per share. In addition, 239,354 stock options with a $13.69 exercise price were canceled and converted into a cash right based on the spread between the merger consideration and the exercise price, while higher-priced options were canceled for no consideration.
Avanos Medical, Inc. director Julie Ann Shimer reported issuer dispositions tied to the closing of a merger effective July 27, 2026. 50,090 shares of common stock were converted into the right to receive $25.00 per share in cash under the merger agreement. In a related step, 12,003 restricted share units were canceled and converted into a cash payment based on the same merger consideration, less applicable taxes. After these transactions, Shimer reported no remaining common stock or restricted share unit holdings.
Avanos Medical, Inc. director Patrick J. O’Leary reported the disposition to the issuer of 54,640 shares of common stock and 12,003 restricted share units on July 27, 2026. In connection with a completed merger, each share and unit was converted into the right to receive $25.00 in cash, leaving him with no reported direct holdings.
AVANOS MEDICAL director Franchini Indrani Lall reported dispositions tied to the company’s merger. On July 27, 2026, she disposed of 4,817 shares of common stock at $25.00 per share, with each share converted into a cash right under the merger terms. On the same date, 12,003 cash-settled restricted share units, each linked to one share of common stock, were canceled and converted into cash based on the same $25.00 merger consideration, less tax withholdings. Following these transactions, the reported holdings for these securities are 0 shares/units.
Avanos Medical, Inc. director Lisa Egbuonu-Davis reported dispositions to the issuer in connection with the company’s merger effective July 27, 2026. She disposed of 13811 shares of common stock and 12003 restricted share units, each converted into the right to receive $25.00 per share in cash, leaving no holdings of these awards.
Avanos Medical director Gary Blackford reported dispositions tied to the cash merger completed on July 27, 2026. A total of 79,590 directly held common shares and 40,000 shares held in family trusts, plus 12,003 cash-settled restricted share units, were converted into the right to receive $25.00 per share in cash. Following these merger-driven transactions, Blackford no longer holds these reported securities.
BLACKFORD GARY reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Gary Blackford received a grant of 12,003 restricted share units on May 8, 2026. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The 12,003 restricted share units were issued to replace units originally granted on January 2, 2025 and will vest when Blackford terminates his service on the company’s Board of Directors.
Egbuonu-Davis Lisa reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical, Inc. director Lisa Egbuonu-Davis received a grant of 12,003 restricted share units on May 8, 2026. Each unit provides a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The new restricted share units fully replace an earlier grant made on January 2, 2025. These units vest when Egbuonu-Davis terminates her service on the company’s Board of Directors. After this grant, she holds 12,003 restricted share units directly as reported in this filing.
Franchini Indrani Lall reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical director Indrani Lall Franchini received a grant of 12,003 restricted share units on May 8, 2026. These units are a cash-settled award, each representing a contingent right to receive a payment equal to the value of one share of Avanos common stock.
The new 12,003 restricted share units replace a prior grant originally issued on January 2, 2025. The units vest when Franchini terminates her service on Avanos Medical’s Board of Directors, aligning the award with her continued board tenure rather than short-term performance.
OLEARY PATRICK J reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Patrick J. O’Leary received a grant of 12,003 restricted share units on May 8, 2026 as compensation. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
These units were issued to replace restricted share units originally granted on January 2, 2025. The award vests when O’Leary’s service on the company’s Board of Directors ends, meaning the units are long-term, service-based compensation rather than an immediate cash payout.
Shimer Julie Ann reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Julie Ann Shimer reported a compensation-related grant of 12,003 restricted share units on May 8, 2026. Each unit is a contingent right to receive a cash payment equal to the value of one share of Avanos common stock.
These restricted share units were issued to replace units originally granted on January 2, 2025, and will vest when Shimer terminates her service on the company’s Board of Directors. Following this award, she holds 12,003 restricted share units directly.
AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported a compensation-related share transaction. On April 22, 2026, 4,228 shares of common stock were surrendered to the company to satisfy tax withholding obligations when 12,225 time-based restricted share units vested. This was a tax-withholding disposition rather than an open-market sale. After the transaction, Galovan directly held 135,596 shares of common stock.
Avanos Medical senior vice president of operations Sigfrido Delgado had shares withheld to cover taxes on a stock award. On the vesting of 16,300 time-based restricted share units, 4,264 shares of common stock were surrendered to Avanos Medical to satisfy tax withholding obligations. Each restricted share unit is economically equivalent to one common share. Following this non-market tax-withholding disposition, Delgado directly holds 55,741 shares of Avanos Medical common stock.
AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported a routine tax-related share disposition. He surrendered 21,194 shares of Common Stock at $14.53 per share to the company to cover tax withholding due when 72,614 time-based restricted share units vested. After this tax-withholding transaction, he directly holds 322,194 shares of Common Stock.
Avanos Medical senior vice president of operations Sigfrido Delgado received new equity compensation awards. He was granted 37,520 employee stock options with an exercise price of $13.69 per share, expiring on March 13, 2036, along with 15,886 time-based restricted share units.
The restricted share units are scheduled to vest in installments between March 13, 2027 and March 13, 2029, and each unit represents one share of common stock. Following these grants, Delgado directly holds 59,434 stock options and 60,005 shares of Avanos Medical common stock. These are compensation awards, not open-market purchases.
Avanos Medical SVP and CFO Scott Michael Galovan received new equity awards. He was granted employee stock options for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,212 shares.
He also received 29,481 shares of Common Stock as a grant, increasing his direct share ownership to 139,824 shares. These awards include time-based restricted share units that vest in scheduled installments on March 13, 2027, March 13, 2028 and March 13, 2029, aligning a portion of his compensation with the company’s long-term performance.
Avanos Medical Chief Executive Officer David Pacitti received new equity awards in the form of stock options and restricted share units. On March 13, 2026, he was granted options to purchase 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
He also received 101,341 time-based restricted share units, each equivalent to one share of Common Stock, increasing his direct Common Stock holdings to 343,388 shares after the grant. These awards vest over three years, with portions scheduled to vest on March 13, 2027, March 13, 2028, and March 13, 2029, aligning his compensation with the company’s long-term performance.
Avanos Medical SVP of Operations Sigfrido Delgado received new equity awards. He was granted 37,782 employee stock options to buy Common Stock at $13.69 per share, expiring on March 13, 2036. He was also granted 15,886 time-based restricted share units that vest in stages between March 2027 and March 2029.
Following these awards, he directly holds 59,696 stock options and 60,005 shares of Common Stock. The TRSUs are the economic equivalent of common shares but will only convert into stock as they vest under Avanos Medical's 2021 Long Term Incentive Plan.
AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported equity compensation grants. He received an employee stock option for 241,021 shares of common stock at an exercise price of $13.69 per share, expiring on March 13, 2036. He also received 101,341 shares of common stock as a grant, bringing his directly held common stock to 343,388 shares after the transaction. Footnotes state the awards are time-based restricted share units under the 2021 Long Term Incentive Plan and will vest in three installments on March 13, 2027, 2028, and 2029 under specified vesting percentages.
AVANOS MEDICAL, INC. reported that its SVP and Chief Financial Officer, Scott Michael Galovan, received new equity awards as part of his compensation. He was granted an employee stock option for 70,115 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,697 options after the grant.
He also received 29,481 time-based restricted share units (TRSUs), increasing his direct Common Stock holdings to 139,824 shares after the award. According to the footnotes, one TRSU equals one share of Common Stock, with vesting in tranches on March 13, 2027, March 13, 2028, and March 13, 2029.
Hurley John Joseph reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical, Inc. reported that Principal Accounting Officer John Joseph Hurley received an award of 2,211 time-based restricted share units under the company’s 2021 Long Term Incentive Plan. These units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, and each unit is economically equivalent to one share of common stock. Following this compensation grant, his reported direct holdings increased to 13,592 shares or share-equivalents.
Avanos Medical SVP and CFO Scott Michael Galovan reported equity awards as part of his compensation. He received an employee stock option grant for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
He was also granted 29,481 time-based restricted share units, each economically equivalent to one share of Common Stock. These RSUs vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029. Following the grants, he holds 139,824 shares of Common Stock directly and 96,212 options.
Avanos Medical, Inc. reported that Chief Executive Officer David Pacitti received new equity awards. He was granted employee stock options for 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
Pacitti also received 101,341 time-based restricted share units under the 2021 Long Term Incentive Plan. These restricted units vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029, and each unit is the economic equivalent of one share of Common Stock. Following these grants, he holds 343,388 shares of Common Stock directly.
Avanos Medical SVP Sigfrido Delgado received new equity awards as part of compensation. On March 13, 2026, he was granted employee stock options for 37,520 shares of Common Stock at an exercise price of $13.69 per share, expiring March 13, 2036. These options vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029. He was also awarded 15,886 time-based restricted share units, each economically equivalent to one share of Common Stock, vesting one-third on March 13, 2027, one-third on March 13, 2028 and one-third on March 13, 2029. Following these awards, Delgado directly holds 60,005 shares of Common Stock and 59,434 derivative securities.
Avanos Medical, Inc. Principal Accounting Officer John Joseph Hurley reported a small tax-related share disposition. On March 9, 2026, 226 shares of common stock were surrendered at $13.29 per share to cover tax withholding when 647 time-based restricted share units vested. After this tax-withholding disposition, Hurley directly holds 11,381 shares of Avanos common stock.
AVANOS MEDICAL, INC. Senior Vice President and Chief Financial Officer Scott Michael Galovan reported a routine tax-related share disposition. On March 9, 2026, 1,119 shares of common stock were surrendered to the company to satisfy tax withholding obligations tied to the vesting of 3,235 time-based restricted share units, each equivalent to one share of common stock. After this tax-withholding transaction, he directly holds 110,343 shares of common stock.
Avanos Medical, Inc. principal accounting officer John Joseph Hurley reported equity award activity in company common stock. On March 6, 2026, 919 performance-based restricted share units vested, resulting in the acquisition of 919 shares at $13.79 per share through an exercise of derivative securities.
On the same date, Hurley surrendered 321, 144, and 211 shares of common stock to the issuer to satisfy tax withholding obligations tied to the vesting of the 919 performance-based RSUs and time-based RSUs of 413 and 604 units. After these transactions, he directly owned 11,607 shares of Avanos common stock.
AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported equity award activity in company stock. On March 6, 2026, he acquired 5,907 shares of common stock at $13.79 per share through the vesting of performance-based restricted share units.
On the same date, he disposed of multiple blocks of common stock at $13.79 per share to satisfy tax withholding obligations tied to the vesting of performance-based and time-based restricted share units, rather than through open-market sales. After these transactions, he directly owned 111,462 shares of Avanos common stock.
Avanos Medical, Inc. executive Kerr W. Holbrook, the SVP and Chief Commercial Officer, reported open-market sales of company common stock. On 11/18/2025, he sold a total of 15,000 shares of Avanos Medical common stock in several transactions at prices ranging from $11.00 to $11.02 per share. After these sales, Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.